IDDF2023-ABS-0104 Metagenomic and Metabolomic Analyses of Colorectal Precancerous Lesions and Temporal Changes of Key Signatures after Polypectomy

Yuhan Zhang,Junjie Qin,Xiaomin Hu,Ming Lu,Bin Lü,Jie Cai,Chenyu Luo,Na Li,Yuwei Zhou,Jingnan Li,Hongda Chen
DOI: https://doi.org/10.1136/gutjnl-2023-iddf.8
2023-01-01
Abstract:BackgroundEvidence of temporal changes in the gut microbiome and circulating metabolome alterations in colorectal precancerous lesions before and after treatment is sparse. We, therefore, aimed to investigate the fecal microbial and plasma metabolomic signatures associated with colorectal adenomas and their temporal changes in advanced colorectal adenomas (AA) before and after polypectomy.MethodsWe included 386 AAs, 324 patients with non-advanced adenoma (NAA), and 329 healthy controls (HC) in a population-based colorectal cancer screening trial. A sub-cohort of 84 AAs who underwent polypectomy at baseline had repeated colonoscopies after two years. All fecal and plasma samples were collected before diagnosis. Omics markers were identified using metagenomics and metabolomics data with validations in the open-source dataset. Temporal changes in AA-related omics signatures were compared in 84 AAs between baseline and two-year after polypectomy (IDDF2023-ABS-0104 Figure 1 (A) Diagram of the study design and data collection (B) Workflow of data analyses).ResultsWe identified elevated abundances of Bacteroides xylanisolvens, Parabacteroides merdae, Parabacteroides distasonis, Flavonifractor plautii, Clostridium symbiosum, and Bacteroides intestinalis in AAs (IDDF2023-ABS-0104 Figure 2. Characteristic of fecal microbiome in AAs, NAAs and HCs (species level). (A) Alpha diversity indices; (B) Gut microbiome similarities; (C-D) Comparisons of gut microbial species between AAs and HCs/NAAs; (E) Log10-transformed relative abundances of the nine differential species), which remained at the same level two-year after polypectomy (p>0.05), as well as nearly half of the AA-related plasma metabolites. We further constructed gut microbial species- and plasma metabolite-based prediction models for AA. However, risks predicted by AA-related gut microbial and plasma metabolic signatures were stable in AAs before and two-year after polypectomy (IDDF2023-ABS-0104 Figure 3. Risks of AA predicted by AA-related gut microbial species and plasma metabolites in AA patients who had no findings of adenoma in repeated colonoscopies (A), or who were diagnosed with NAA in repeated colonoscopies (B), or who were diagnosed with AA in repeated colonoscopies (C)).ConclusionsGut microbial signatures associated with AA remained stable for two years after polypectomy, indicating the significance of gut microbiota reconstruction in CRC prevention.
What problem does this paper attempt to address?